MAIA Biotechnology, Inc. highlighted positive efficacy data from the Phase 2 clinical trial, THIO-101, evaluating ateganosine sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer (NSCLC).
The estimated median progression free survival in third-line treatment was 5.6 months, surpassing the standard of care threshold of 2.5 months.
Median overall survival was 17.8 months, with consistent data from previous readouts, and two patients completed 33 cycles of therapy showcasing potential for extended dosing.
Positive Efficacy Data
THIO-101 demonstrated a median progression free survival of 5.6 months, emphasizing its effectiveness compared to standard treatments.
Extended Dosing Potential
Two patients completed 33 therapy cycles, indicating ateganosine's potential for longer patient survival.
Phase 2 Expansion Trial
MAIA plans to further validate ateganosine's efficacy in the THIO-101 Phase 2 expansion trial starting in July 2025.
- The efficacy data from THIO-101 suggests a promising outlook for ateganosine in treating advanced NSCLC patients.
- The positive results indicate a potential shift in the standard of care for non-small cell lung cancer treatment towards targeted immunotherapies like ateganosine.
MAIA Biotechnology's THIO-101 Phase 2 trial results demonstrate significant efficacy and potential in treating advanced NSCLC. The data supports the company's commitment to developing innovative cancer therapies.